Digital Technology Combined With Blood Marker Screening and Diagnosis for Community Populations Based on Classification Theory: an Integrated Study

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorFirst Hospital of China Medical University

About this trial

Our research hypothesis is as follows: A step - by - step screening strategy based on screening technologies can resolve the issue of insufficient efficiency in the traditional scale - based screening model. Meanwhile, performing pathological diagnoses on patients with suspected cognitive impairment identified through screening is conducive to the further implementation of etiology - based treatment and intervention, thus bringing benefits to patients at the earliest possible stage.

By exploring the characteristic changes in gait, facial expressions, and language of patients with suspected cognitive impairment and analyzing their diagnostic efficiency for cognitive impairment patients, new ideas can be provided for the early diagnosis of the disease.

Through longitudinal observation of the changes in disease - related information during the progression and transformation of the disease, a predictive model for the early diagnosis of cognitive impairment and the prediction of disease progression can be constructed.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adults aged 50 and above;

Residents of this community for at least one year, with established medical records;

Deny a history of cognitive impairment diseases (mild cognitive impairment, dementia, Alzheimer's, etc.) and the use of anti-dementia drugs (cholinesterase inhibitors or memantine, etc.);

Agree to participate in the study;

Disqualifiers

Self-reported or confirmed through inquiry that there is a severe mental disorder, such as bipolar disorder or schizophrenia, etc.

Suffering from a disease that makes it impossible to complete the cognitive assessment.

Trial population

Residents aged 50 and above who were included in the communities from December 2025 to April 2026

Trial design

Design model

Ecologic or community

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

1,000 Participants
are grouped into 2 trial groups
Group A: Cognitive impairment group
Group B: Healthy population group

Trial outcomes

Primary outcomes

1

The diagnostic efficiency of the cognitive impairment screening and diagnosis protocol

The diagnostic efficiency will be measured by the area under curve(AUC)of receiver operating characteristic(ROC)curve.

Time frame
1 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: